Asfotase alpha Drug Asset Due Diligence Report 2026

This Asfotase alpha Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Asfotase alpha can convert its Fusion protein profile and ALP biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Asfotase alpha (query alias: asfotase alfa)
Modality / target	Fusion protein; ALP; ALP modulators
Highest global status	Approved
Originator	Alexion Pharmaceuticals, Inc.
Active developers	AstraZeneca Korea Co. Ltd., Alexion Pharmaceuticals, Inc., Alexion Europe SAS

The MCP disease footprint includes Hypophosphatasia, Infantile, Hypophosphatasia. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT04189315	Phase 4	Withdrawn	Not disclosed	Change From Baseline To Week 36 In Plasma Concentrations Of Inorganic Pyrophosphate (PPi) In Group 1
NCT06079372	Phase 3	Active, not recruiting	43	Number of Participants with Treatment-emergent Adverse Events (TEAEs)
NCT04195763	Not Applicable	Completed	50	Change From Baseline In Patient Reported Outcomes (PROs) Questionnaire Scores

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Pediatric onset hypophosphatasia: a case report

Phase 2; n=not disclosed; evaluation: not stated. Reported fields: Serum ALP = 125 U/L

MOBILITY AND HEALTH-RELATED QUALITY OF LIFE IN ADULTS WITH PAEDIATRIC-ONSET HYPOPHOSPHATASIA TREATED WITH ASFOTASE ALFA: INTERIM ANALYSIS FROM THE UK MANAGED ACCESS AGREEMENT

Not Applicable; n=25; evaluation: Positive. Reported fields: 6MWT distance walked = 130.0 m

Efficacy and Safety of Asfotase Alfa in Infants and Young Children With Hypophosphatasia: A Phase 2 Open-Label Study

Phase 2; n=69; evaluation: Positive. Reported fields: RGI-C(1-year) = 2.0 point

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Asfotase alpha addresses Hypophosphatasia, Infantile, Hypophosphatasia. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Fusion protein—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 5 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: ALP records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2026-02-18	Gut-focused Rasayana ingests gastrointestinal candidate in $36M licensing deal	Pending	US$0.3M upfront; US$38.0M milestones
2023-08-10	Clinigen divests global rights to four cancer support therapies to CNX Therapeutics	Approved	Financial terms not disclosed
2020-05-27	Synthetic Biologics has entered into an exclusive option agreement with Massachusetts General Hospital	Phase 1	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO